By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Tobira Therapeutics Inc. 

214 Carnegie Center
Suite 306
Princeton  New Jersey  08540  U.S.A.
Phone: 609-897-1102 Fax: n/a


Company News
Tobira’s Cenicriviroc Reduces Inflammation And Fibrosis In Animal Models Of Chronic Liver And Kidney Disease Including NASH 6/28/2016 8:41:37 AM
Tobira’s Cenicriviroc Shown To Reduce Liver Injury In Independent Research Published In The Journal Hepatology 6/17/2016 8:49:46 AM
Tobira To Participate In Two Conferences In June 5/31/2016 9:21:48 AM
Tobira Announces Publication Of Phase 1 Study Results Showing Cenicriviroc Safety In Cirrhotic Patients 5/13/2016 7:37:30 AM
Tobira Reports First Quarter 2016 Financial And Business Results 5/10/2016 7:25:44 AM
Tobira Announces Interim 12-Week Results From The ORION Study 5/2/2016 7:40:13 AM
Tobira Announces Upcoming Presentations On Biomarkers For NASH At Two Scientific Meetings 4/22/2016 6:31:16 AM
Bay Area's Tobira Strikes a $74.5 Million Evogliptin and Cenicriviroc Deal with Dong-A ST 4/11/2016 6:35:42 AM
Tobira Therapeutics Inc. To Present At The 15th Annual Needham Healthcare Conference 4/5/2016 7:42:26 AM
Tobira Therapeutics Inc. Release: Independent Research To Be Presented At International Liver Congress Shows Cenicriviroc Improves Steatohepatitis And Liver Fibrosis In NASH Model 3/31/2016 10:33:24 AM